Skip to main content
Premium Trial:

Request an Annual Quote

Novasep, Chromatide Extend Synthetic Peptide, Oligo Partnership

NEW YORK (GenomeWeb News) – Chromatide and Novasep have agreed to extend a research partnership focused on developing peptide and oligonucleotide synthesis technology, Novasep said Friday.
 
Novasep said the companies plan to combine its synthesis and purification services, which pharmaceutical companies use to produce pure peptides and oligonucleotides, with Chromatide’s experience in peptide and oligonucleotide synthesis, including production of novel resins and instruments.
 
“Peptide manufacturers lack a cost efficient, automated solid phase synthesis technology,” explained Novasep Process Pharma Business Unit President Jean Blehaut, adding that the combined systems “will allow us to provide a unique, global process solution for peptides” and for oligonucleotide makers.
 
Novasep plans to launch the synthesis systems the companies have developed later this year, Chromatide CSO Don Wellings said in a statement.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.